The University of Hawai‘i Cancer Center announced that UH alumnus and philanthropist businessman Jay H. Shidler has donated $1 million to start the Director’s Innovation Fund to allow Director Naoto T. Ueno to advance his vision for the research at the center.
Pasi A. Jänne received the GO2 for Lung Cancer’s 2024 Bonnie J. Addario Lectureship Award.
LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.
NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.
A new donor-funded project is offering free assistance to newly-diagnosed cancer patients across Los Angeles County to help them navigate the appointments, tests, options, and challenges that come with a life-altering diagnosis.
Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.
The American Society of Clinical Oncology has brought together 12 groups of cancer care delivery professionals to initiate a program aimed to improve health equity.
Cleveland Clinic-led research has identified geographic areas in the United States where strategic efforts to promote colorectal cancer screening could help reduce health care gaps affecting Hispanic/Latino communities.
People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.
Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
